GSA Capital Partners’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-209,292
| Closed | -$536K | – | 2060 |
|
|
2025
Q1 | $536K | Sell |
209,292
-96,457
| -32% | -$247K | 0.05% | 761 |
|
|
2024
Q4 | $575K | Sell |
305,749
-129,464
| -30% | -$243K | 0.04% | 783 |
|
|
2024
Q3 | $444K | Buy |
435,213
+33,969
| +8% | +$34.7K | 0.03% | 991 |
|
|
2024
Q2 | $469K | Sell |
401,244
-92,327
| -19% | -$108K | 0.03% | 1009 |
|
|
2024
Q1 | $622K | Sell |
493,571
-50,667
| -9% | -$63.9K | 0.05% | 754 |
|
|
2023
Q4 | $969K | Buy |
544,238
+47,457
| +10% | +$84.5K | 0.08% | 414 |
|
|
2023
Q3 | $825K | Buy |
+496,781
| New | +$825K | 0.07% | 509 |
|
|
2022
Q1 | – | Sell |
-24,527
| Closed | -$20K | – | 1735 |
|
|
2021
Q4 | $20K | Sell |
24,527
-230,344
| -90% | -$188K | ﹤0.01% | 1359 |
|
|
2021
Q3 | $339K | Buy |
+254,871
| New | +$339K | 0.03% | 939 |
|
|
2021
Q1 | – | Sell |
-10,042
| Closed | -$36K | – | 1398 |
|
|
2020
Q4 | $36K | Buy |
+10,042
| New | +$36K | 0.01% | 1143 |
|